Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

Item
http://www.wikidata.org/entity/Q38535099
Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDXAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study.Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.The context of prostate cancer genomics in personalized medicine.miR-301a expression: A prognostic marker for prostate cancer.Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.Metabolic changes in patients with prostate cancer during androgen deprivation therapy.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.Current treatment strategies for advanced prostate cancer.Targeted α Therapies for the Treatment of Bone Metastases.No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
P2860

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

Item
http://www.wikidata.org/entity/Q38535099
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.
@en
type
label
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.
@en
prefLabel
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698